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Abstract
Background: Severe unconjugated hyperbilirubinemia may cause deafness. In the Netherlands, 25% lower total serum
bilirubin (TSB) treatment thresholds were recently implemented for preterm infants.
Objective: To determine the rate of hearing loss in jaundiced preterms treated at high or at low TSB thresholds.
Design/Methods: In this retrospective study conducted at two neonatal intensive care units in the Netherlands, we included
preterms (gestational age ,32 weeks) treated for unconjugated hyperbilirubinemia at high or low TSB thresholds. Infants
with major congenital malformations, syndromes, chromosomal abnormalities or toxoplasmosis, rubella, cytomegalovirus,
herpes, syphilis, and human immunodeficiency infections were excluded. We analyzed clinical characteristics and TSB levels
during the first ten postnatal days. After two failed automated Auditory Brainstem Response (ABR) tests we used the results
of the diagnostic ABR examination to define normal, unilateral, and bilateral hearing loss (.35 dB).
Results: There were 479 patients in the high and 144 in the low threshold group. Both groups had similar gestational ages
(29.5 weeks) and birth weights (1300 g). Mean and mean peak TSB levels were significantly lower after the implementation
of the novel thresholds: 152643 mmol/L and 212652 mmol/L versus 131637 mmol/L and 188646 mmol/L for the high
versus low thresholds, respectively (P,0.001). The incidence of hearing loss was 2.7% (13/479) in the high and 0.7% (1/144)
in the low TSB threshold group (NNT= 50, 95% CI, 25–3302).
Conclusions: Implementation of lower treatment thresholds resulted in reduced mean and peak TSB levels. The incidence of
hearing impairment in preterms with a gestational age ,32 weeks treated at low TSB thresholds was substantially lower
compared to preterms treated at high TSB thresholds. Further research with larger sample sizes and power is needed to
determine if this effect is statistically significant.
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Introduction
In 2007, lower treatment thresholds were introduced for the
management of unconjugated hyperbilirubinemia in Dutch
preterm infants of less than 32 weeks of gestation. [1] Universal
aim of these guidelines for jaundiced preterm infants is to reduce
the incidence of hyperbilirubinemia and bilirubin neurotoxicity.
However, legitimate evidence on harmful total serum bilirubin
(TSB) levels and safe TSB thresholds in preterm infants is
lacking.[2–6] Auditory dysfunction has been observed in preterm
neonates at TSB levels below exchange transfusion thresholds. It is
known that the neural auditory pathway is one of the most
sensitive areas of the central nervous system for bilirubin
neurotoxicity. [7] Free unconjugated bilirubin (UCBfree), the
fraction of UCB not bound to plasma proteins (mainly albumin),
can translocate across the blood-brain barrier and cause neuro-
toxicity. In line with this is the increased likelihood of an abnormal
hearing screening test, i.e. an automated auditory brainstem
response (AABR), with increasing UCBfree levels in preterm infants
of 34 or more weeks of gestation. [8,9] In these late preterm
infants, no relation was demonstrated between an abnormal
AABR and the TSB level. In younger preterm infants, the exact
relation between TSB levels and hearing loss, including AABR,
complete audiologic examination, and a diagnostic ABR is largely
unknown. These preterm infants are especially prone for impeding
bilirubin neurotoxicity and subtle ABR changes have been
demonstrated at rather low TSB levels of 170 mmol/L. [10,11]
Introduction of novel consensus – based management guidelines of
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preterm infants with unconjugated hyperbilirubinemia in 2007
enabled us to compare the incidence of hearing impairment in
jaundiced preterm infants treated at high TSB thresholds or at low
TSB thresholds.
In addition, the effect of a variety of demographic and clinical
characteristics on hearing impairment was analyzed.
Methods
Ethics Statement
According to the Research involving Human Subjects Act
(WMO), because this study only includes retrospective research
with data, it is not subject to an ethics review and does not need to
include informed consent from the subjects, as the data was used
anonymously. This study fulfils all the requirements for test subject
anonymity and is in accordance with regulations of the review
boards of the participating hospitals.
Patients
Preterm infants of less than 32 weeks of gestation were included
when admitted to one of the two participating NICU centers in
two time periods: between January 2005 and December 2006, i.e.
before introduction of the novel thresholds, and between March
2007 and March 2008. Exclusion criteria consisted of major
congenital malformations, clinical syndromes, chromosomal ab-
normalities or TORCH (toxoplasmosis, rubella, cytomegalovirus,
herpes, syphilis, and human immunodeficiency viral). These
infections were excluded as these conditions are likely to affect
hearing status. In addition, infants who died before the automated
auditory brainstem response (AABR) was carried out were
excluded.
Treatment
Eligible infants admitted in 2005 and 2006 to one of the
participating NICU centers were included and used as a control
group: the high threshold group. In this group, treatment of
unconjugated hyperbilirubinemia was applied according to
identical guidelines for four (birth weight) categories: ,1000
grams, 1000–1500 grams, 1500–2500 grams, and term newborns.
In April 2007, a new ‘‘consensus based’’ guideline for preterm
infants was implemented in the Netherlands. Treatment thresholds
were ,25% lower in the novel guideline. [1,12] Eligible infants
between April 2007 and March 2008 were included in this low
threshold group. Five birth weight categories were used: ,1000
grams, 1000–1250 grams, 1250–1500 grams, 1500–2000 grams
and .2000 grams. In both treatment groups, preterm infants were
classified as standard or high risk depending on the presence of
commonly applied risk factors: asphyxia (defined as an Apgar
Score ,3 after 5 minutes), hypoxemia (paO2,5.3 kPa for more
than 2 hours in the last 24 hours), acidosis (pH,7.15 for more
than 1 hour in the last 24 hours), hemolysis (as demonstrated by a
positive Coombs’ reaction), extreme low birth weight (birth weight
,1000 grams), sepsis with circulatory insufficiency, meningitis,
and intracranial haemorrhage (ICH) grade 2 or more according to
Papile. In both centers, irradiance of phototherapy light sources
was measured to comply with the international recommended
intensity of phototherapy (center 1:10.562.5 mW/cm2/nm; center
2:7.463.3 mW/cm2/nm; p= 0.11). [13].
Bilirubin Testing
Total serum bilirubin was tested in the first 10 postnatal days or
when clinically indicated. Bilirubin measurements were performed
using routine laboratory techniques. In each infant, the mean and
mean peak of TSB measurements were calculated and used for
analysis.
Hearing Testing
All Dutch NICUs participate in a two-stage AABR neonatal
hearing programme. The instruments’ algorithm of the AABR
assumes an infant as passing the test when the acquired data
obtained at 35 dB fits with 99.96% likelihood a template
composed of auditory brainstem responses from normal hearing
newborns. [14] Infants who failed the two AABR stages were
referred to an audiological centre for further diagnostics, including
conventional ABR, considered as the gold standard for detection
of hearing level. The result of ABR was considered impaired when
the infant’s ABR hearing levels exceeded 35 dB in at least one ear.
Those infants who passed the screening were assumed to have
normal hearing thresholds at that time.
Statistics
Descriptive analyses were performed to determine the incidence
of hearing loss and background characteristics in the high and low
threshold group. Sensitivity and specificity of mean and mean peak
TSB levels were evaluated using receiver-operating characteristics
(ROC) curves.
Results
Figure 1 shows the number of included infants. The eligible
cohort existed of 893 infants. A substantial number 270 (30%) was
excluded, most often due to the absence of any bilirubin
measurements (14%), death (11%), or predefined exclusion criteria
(5%). We studied 623 (70%) of preterm infants who were admitted
during the study period, 144 were treated at low thresholds and
479 at high thresholds, respectively. The infants of the low and
high thresholds group were similar with respect to gestational age
and birth weight (Table 1). Infectious complications, i.e., sepsis
and meningitis, were more often diagnosed in preterm infants
treated according to the novel bilirubin thresholds.
No difference was observed in the proportion of infants who
were hospitalized $ 12 days at intensive care, which is seen as an
independent risk indicator for hearing loss. [15] As shown in
Table 1, preterm infants of the two threshold groups showed
significant differences in mean and mean peak TSB levels
(P,0.001). Mean and mean peak TSB levels were ,20 mmol/L
and 25 mmol/L lower in preterm infants of the low threshold
group. The incidence of hearing loss was substantially higher in
preterm infants treated at high TSB thresholds (2.7%) compared
to infants treated at low TSB thresholds (0.7%), resulting in a
Number Needed to Treat of 50 (95% CI: 25–3302). The
difference was not statistically significant (P = 0.21), probably
because of insufficient power. Consanguinity was not present in
infants with hearing loss. A positive familial history of hearing loss
was found in one infant (a brother of the mother) with hearing loss
in the high threshold group (NS). Peak TSB levels occurred
significantly earlier (,0.5 days) in preterm infants of the low
threshold group. To assess whether a specific TSB level existed to
predict hearing loss, ROC curves were constructed for mean TSB
and mean peak TSB levels. Figure 2 shows that neither mean TSB
level nor mean peak TSB level is a robust predictor of hearing loss:
both areas under the curve (AUC) were approximately 0.5. In
agreement with this we found similar mean and mean peak TSB
levels in infants treated without (n = 609) and with (n = 14) hearing
loss (148643 mmol/L vs. 139640 mmol/L and 206652 mmol/L
vs. 210658 mmol/L; no hearing loss vs. hearing loss, resp.).
Hyperbilirubinemia and Hearing Loss
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Discussion
This retrospective cohort study demonstrates that introduction
of lower treatment thresholds in preterm infants results in
significantly lower mean and mean peak TSB levels. Treatment
according to novel treatment thresholds did not result in a
significant reduction of hearing impairment, albeit a ,75%
reduction in the incidence of hearing loss. Finally, and in analogy
to previous data in term infants, it appeared that TSB level is also
a poor predictor of hearing loss in preterm infants.
In 2007, the Dutch Society of Pediatrics approved and
recommended a novel, ‘‘consensus-based’’ guideline on unconju-
gated hyperbilirubinemia in preterm infants. [1] Similar to other
two existing guidelines of the United Kingdom and Norway, and
the recently published ‘‘approach’’ of an expert committee in the
USA, management of jaundiced preterm infants is now more
uniform. [3,16,17] However, legitimate evidence on these applied
Figure 1. Flow chart with included and excluded infants of both NICU centers.
doi:10.1371/journal.pone.0062858.g001
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treatment thresholds is lacking: to the best of our knowledge, long-
term data on auditory or neurological outcome treated according
to these guidelines are not at hand. As the auditory pathway is
highest susceptible to bilirubin neurotoxicity, we chose next to
bilirubin levels, the incidence of hearing impairment as a tool to
evaluate the effectiveness of the novel Dutch guideline.
Infants treated according to the ,25% lower thresholds had
lower TSB levels: we found a reduction of ,15% in mean and
mean peak TSB levels, supporting an effective implementation of
the new guideline.
Yet, auditory impairment in preterm infants may also occur at
TSB levels below applied treatment thresholds, and - despite the
rather low TSB levels- similar TSB levels have contributed to
profound neurological impairment including sensoneurinal hear-
ing loss in extreme or very low birth weight infants.[4,18–20].
The incidence of hearing loss in the control group treated at
higher TSB thresholds was in agreement with previous data: in a
representative NICU population (10830 neonates with a mean
(SD) gestational age 28.5 (1.6) weeks and birth weight of 1039
(256) g) the prevalence of hearing loss was 3.2% (95%-CI 2.6–4.1).
[21] The incidence of hearing loss in preterm infants treated
according to lower treatment thresholds was lower, whereas peak
bilirubin levels occurred ,0.5 days earlier and the clinical
characteristics of these preterm neonates were significantly worse:
infectious diseases occurred more often in this particular group. It
is well known that sepsis and meningitis can result in severe
neurodevelopmental abnormalities, including hearing loss. It is
therefore tempting to speculate on the ‘‘protective’’ role of these
novel, and lower treatment thresholds for jaundiced preterm
infants. In agreement with this is data on high TSB levels which
are known to significantly increase the risk of hearing loss, [22]
although considerable overlap in TSB levels between very low
birth weight infants with and without sensoneurinal hearing
impairment has been reported. [18] The broad range in TSB
levels in infants with hearing loss in our study and the occurrence
of auditory impairment in preterm infants whose TSB levels never
exceeded TSB thresholds, illustrate that TSB only is not a sensitive
parameter to predict hearing loss, but that - for that matter - free
bilirubin (Bf) may act as an important pathophysiological co-
determinant of audiological dysfunction. In a retrospective case-
control study in preterm and term infants (gestational ages 24–42
weeks) the role of Bf on audiologic dysfunction was delineated. [9]
An abnormal AABR was associated with elevated levels of Bf and
– even stronger with an elevated Bf/TSB ratio, which reflects the
possibility of bilirubin entering the brain (i.e., Bf), and also the total
bilirubin load of the infant (i.e., TSB). Data from the Neonatal
Research Network confirmed the deleterious neurotoxic effects of
Bf extremely low birth weight infants. [23] Levels of Bf would thus
have been very informative, but were unavailable in our study. We
acknowledge few other limitations: First, data on the postnatal
course of TSB levels and applied treatment (phototherapy and
exchange transfusion) are missing. Thus, the existence of
prolonged bilirubin toxicity can only be speculated upon, whereas
prolonged elevated TSB levels may pose an additional risk of
ototoxicity in VLBW preterm infants. [24] Secondly, the
retrospective character of this relative small study and concomitant
selection bias does not provide sufficient power to adopt or adapt
current treatment thresholds. Approximately 750 infants per
group are necessary to detect a statistical significance difference
between the reported prevalences of 2.7% and 0.7% (with an
alpha of 0.05, and power of 80%). We are therefore cautious to
claim any evidence on the applied treatment thresholds for
preterm infants.
Despite these limitations, this is the first study to report on
evaluation of a consensus-based national guideline in preterm
infants with unconjugated hyperbilirubinemia regarding TSB
levels and - unlike other studies - a formal diagnostic ABR (and not
a screening ABR) as outcome parameters.
We conclude that successful implementation of lower TSB
thresholds results in a reduction of mean TSB and mean peak TSB
levels, and that larger studies - which preferably also provide data
on Bf levels - are needed to establish a statistically significant effect
of hyperbilirubinemia on hearing loss in very preterm infants.
Table 1. Clinical characteristics of jaundiced preterm infants








Gestational age, wks 29.561.7 29.561.6
Birth weight, g 13006350 13106310
Apgar score at 19 7 [0–10] 6 [1–10]
Mechanical ventilation, n (%) 273 (57) 93 (65)
Sepsis, n (%) 163 (34) 82 (57)*
Meningitis, n (%) 7(2) 9 (6)*
Intracerebral bleeding, n (%) 15 (3) 4 (3)
Intensive care, days 16 [2–121] 17 [3–100]
Intensive care $ 12 days, n (%) 310 (65) 103 (72)
TSB mean, mmol/L 152643 131637*
TSB max, mmol/L 212652 188646*
Postnatal age of TSB max, day# 5.261.7 4.761.7*
No hearing loss, n/N (%) 466/479 (97.3) 143/144 (99.3)
Hearing loss, n/N (%) 13/479 (2.7) 1/144 (0.7)
Data represent mean (6 SD) or median [ranges];
#data are based on 453 and 137 infants, resp.;
*P,0.005.
doi:10.1371/journal.pone.0062858.t001
Figure 2. ROC curves of TSB levels as predictor of hearing loss.
doi:10.1371/journal.pone.0062858.g002
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